微RNA作为生物标志物和精神分裂症认知功能障碍的分子媒介
Nabila M Adly1, Dalia Khalifa2, Shaimaa Abdel-Ghany3
1Department of Medical Biotechnology, College of Biotechnology, Misr University for Science and Technology, P. O. Box 77, Giza, Egypt.
Journal of neural transmission (Vienna, Austria : 1996)
|August 8, 2025
概括
失调的microRNAs (miRNAs) 与精神分裂症的认知缺陷有关. 体液中的这些分子可能为诊断精神分裂症和改善治疗提供了一种新的客观方法.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 精神病学是一个精神病学.
背景情况:
- 精神分裂症是一种慢性疾病,具有影响日常生活的认知症状.
- 目前的诊断依赖于主观症状评估 (DSM-5),导致延迟和各种分类.
- 精神分裂症的认知功能障碍缺乏有效的治疗方法.
研究的目的:
- 审查微RNAs (miRNAs) 在精神分裂症相关认知缺陷中的作用.
- 在认知障碍中探索miRNA失调的分子机制.
- 讨论miRNAs作为精神分裂症的非侵入性生物标志物的潜力.
主要方法:
- 关于miRNAs和精神分裂症的研究的文献综述.
- 对神经发育,突触可塑性和神经递质信号传递中的miRNA功能进行分析.
- 检查外围生物流体中miRNA存在的生物标志物潜力.
主要成果:
- 失调的miRNAs与精神分裂症认知缺陷的分子途径有关.
- miRNAs影响神经发育和突触可塑性等关键过程.
- 在外围生物流体中可以检测到miRNAs,这表明生物标记物的实用性.
结论:
- 失调的miRNAs在精神分裂症相关的认知功能障碍中起着至关重要的作用.
- miRNAs为早期检测和分类提供了作为非侵入性生物标志物的潜力.
- 了解miRNA机制可能会导致新的诊断工具和针对精神分裂症的个性化治疗.
相关概念视频
Negative and Cognitive Symptoms of Schizophrenia
123
Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
123
Biological Causes of Schizophrenia
149
Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
149
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
206
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
206
MicroRNAs
3.1K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
Alzheimer's Disease: Overview
668
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
668


